Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 182

1.

Tracheobronchial involvement of relapsing polychondritis.

de Montmollin N, Dusser D, Lorut C, Dion J, Costedoat-Chalumeau N, Mouthon L, Chassagnon G, Revel MP, Puéchal X.

Autoimmun Rev. 2019 Sep;18(9):102353. doi: 10.1016/j.autrev.2019.102353. Epub 2019 Jul 16. Review.

PMID:
31323366
2.

Rheumatoid arthritis-associated bronchiectasis.

Puéchal X, Bienvenu T, Dusser D.

Lancet. 2019 May 18;393(10185):2035-2036. doi: 10.1016/S0140-6736(19)30020-0. No abstract available.

PMID:
31106745
3.

Safety of tiotropium in patients with asthma.

Dusser D, Ducharme FM.

Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466618824010. doi: 10.1177/1753466618824010. Review.

4.

Postoperative outcomes of frequent exacerbator patients with Chronic Obstructive Pulmonary Disease after resection of Non-Small Cells Lung Cancer.

Demiri S, Lorut C, Rabbat A, Luu van Lang D, Lefebvre A, Regnard JF, Samama CM, Dusser D, Roche N, Alifano M.

COPD. 2018 Jun-Aug;15(4):361-368. doi: 10.1080/15412555.2018.1519784. Epub 2018 Oct 30.

PMID:
30375895
5.

[White card to the Hôpital Cochin].

Dusser D.

Rev Pneumol Clin. 2018 Oct;74(5):265-266. doi: 10.1016/j.pneumo.2018.09.007. Epub 2018 Oct 15. French. No abstract available.

PMID:
30337200
6.

Treatment of exacerbations as a predictor of subsequent outcomes in patients with COPD.

Calverley PM, Anzueto AR, Dusser D, Mueller A, Metzdorf N, Wise RA.

Int J Chron Obstruct Pulmon Dis. 2018 Apr 23;13:1297-1308. doi: 10.2147/COPD.S153631. eCollection 2018.

7.

Determinants of exacerbation risk in patients with COPD in the TIOSPIR study.

Calverley PM, Tetzlaff K, Dusser D, Wise RA, Mueller A, Metzdorf N, Anzueto A.

Int J Chron Obstruct Pulmon Dis. 2017 Nov 29;12:3391-3405. doi: 10.2147/COPD.S145814. eCollection 2017.

8.

DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis.

Viel M, Hubert D, Burgel PR, Génin E, Honoré I, Martinez B, Gaitch N, Chapron J, Kanaan R, Dusser D, Girodon E, Bienvenu T.

Clin Respir J. 2016 Nov;10(6):777-783. doi: 10.1111/crj.12288. Epub 2015 Apr 15.

PMID:
25763772
9.

Safety and tolerability of once-daily tiotropium Respimat(®) as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: A pooled safety analysis.

Dahl R, Engel M, Dusser D, Halpin D, Kerstjens HAM, Zaremba-Pechmann L, Moroni-Zentgraf P, Busse WW, Bateman ED.

Respir Med. 2016 Sep;118:102-111. doi: 10.1016/j.rmed.2016.07.001. Epub 2016 Jul 2.

10.

Tiotropium safety in 'real-world' populations: Response to Schmiedl, et al. in the British Journal of Clinical Pharmacology.

Wise R, Anzueto A, Dahl R, Dusser D, Calverley P.

Br J Clin Pharmacol. 2016 Aug;82(2):562-3. doi: 10.1111/bcp.12972. Epub 2016 May 19. No abstract available.

11.

CFTR and/or pancreatitis susceptibility genes mutations as risk factors of pancreatitis in cystic fibrosis patients?

Gaitch N, Hubert D, Gameiro C, Burgel PR, Houriez F, Martinez B, Honoré I, Chapron J, Kanaan R, Dusser D, Girodon E, Bienvenu T.

Pancreatology. 2016 Jul-Aug;16(4):515-22. doi: 10.1016/j.pan.2016.03.021. Epub 2016 Apr 5.

PMID:
27086061
12.

Pharmacodynamics and Pharmacokinetics Following Once-Daily and Twice-Daily Dosing of Tiotropium Respimat® in Asthma Using Standardized Sample-Contamination Avoidance.

Beeh KM, Kirsten AM, Dusser D, Sharma A, Cornelissen P, Sigmund R, Moroni-Zentgraf P, Dahl R.

J Aerosol Med Pulm Drug Deliv. 2016 Oct;29(5):406-415. Epub 2016 Feb 9.

13.

Differences in outcomes between GOLD groups in patients with COPD in the TIOSPIR(®) trial.

Dusser D, Wise RA, Dahl R, Anzueto A, Carter K, Fowler A, Calverley PM.

Int J Chron Obstruct Pulmon Dis. 2016 Jan 20;11:133-45. doi: 10.2147/COPD.S97924. eCollection 2016.

14.

[Small airway diseases and immune deficiency].

Burgel PR, Bergeron A, Knoop C, Dusser D.

Rev Mal Respir. 2016 Feb;33(2):145-55. doi: 10.1016/j.rmr.2015.11.003. Epub 2016 Feb 4. Review. French.

PMID:
26854188
15.

Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial.

Dahl R, Calverley PM, Anzueto A, Metzdorf N, Fowler A, Mueller A, Wise R, Dusser D.

BMJ Open. 2015 Dec 29;5(12):e009015. doi: 10.1136/bmjopen-2015-009015.

16.

Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial.

Wise R, Calverley PM, Dahl R, Dusser D, Metzdorf N, Müller A, Fowler A, Anzueto A.

NPJ Prim Care Respir Med. 2015 Nov 5;25:15067. doi: 10.1038/npjpcrm.2015.67.

17.

Prevalence and reversibility of lung hyperinflation in adult asthmatics with poorly controlled disease or significant dyspnea.

Perez T, Chanez P, Dusser D, Devillier P.

Allergy. 2016 Jan;71(1):108-14. doi: 10.1111/all.12789. Epub 2015 Nov 6.

PMID:
26466328
18.

Renin-associated hypertension after bronchial artery embolization in cystic fibrosis.

Coolen N, Gouya H, Kanaan R, Honoré I, Chapron J, Hubert D, Legmann P, Dusser D, Burgel PR.

J Cyst Fibros. 2016 Mar;15(2):213-5. doi: 10.1016/j.jcf.2015.09.003. Epub 2015 Sep 26.

19.

The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes.

Anzueto A, Wise R, Calverley P, Dusser D, Tang W, Metzdorf N, Dahl R.

Respir Res. 2015 Sep 15;16:107. doi: 10.1186/s12931-015-0269-4.

20.

An official American Thoracic Society/European Respiratory Society statement: research questions in COPD.

Celli BR, Decramer M, Wedzicha JA, Wilson KC, Agustí AA, Criner GJ, MacNee W, Make BJ, Rennard SI, Stockley RA, Vogelmeier C, Anzueto A, Au DH, Barnes PJ, Burgel PR, Calverley PM, Casanova C, Clini EM, Cooper CB, Coxson HO, Dusser DJ, Fabbri LM, Fahy B, Ferguson GT, Fisher A, Fletcher MJ, Hayot M, Hurst JR, Jones PW, Mahler DA, Maltais F, Mannino DM, Martinez FJ, Miravitlles M, Meek PM, Papi A, Rabe KF, Roche N, Sciurba FC, Sethi S, Siafakas N, Sin DD, Soriano JB, Stoller JK, Tashkin DP, Troosters T, Verleden GM, Verschakelen J, Vestbo J, Walsh JW, Washko GR, Wise RA, Wouters EF, ZuWallack RL; ATS/ERS Task Force for COPD Research.

Eur Respir Rev. 2015 Jun;24(136):159-72. doi: 10.1183/16000617.00000315. Review.

21.

An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease.

Celli BR, Decramer M, Wedzicha JA, Wilson KC, Agustí A, Criner GJ, MacNee W, Make BJ, Rennard SI, Stockley RA, Vogelmeier C, Anzueto A, Au DH, Barnes PJ, Burgel PR, Calverley PM, Casanova C, Clini EM, Cooper CB, Coxson HO, Dusser DJ, Fabbri LM, Fahy B, Ferguson GT, Fisher A, Fletcher MJ, Hayot M, Hurst JR, Jones PW, Mahler DA, Maltais F, Mannino DM, Martinez FJ, Miravitlles M, Meek PM, Papi A, Rabe KF, Roche N, Sciurba FC, Sethi S, Siafakas N, Sin DD, Soriano JB, Stoller JK, Tashkin DP, Troosters T, Verleden GM, Verschakelen J, Vestbo J, Walsh JW, Washko GR, Wise RA, Wouters EF, ZuWallack RL; ATS/ERS Task Force for COPD Research.

Am J Respir Crit Care Med. 2015 Apr 1;191(7):e4-e27. doi: 10.1164/rccm.201501-0044ST.

PMID:
25830527
22.

An official American Thoracic Society/European Respiratory Society statement: research questions in COPD.

Celli BR, Decramer M, Wedzicha JA, Wilson KC, Agustí A, Criner GJ, MacNee W, Make BJ, Rennard SI, Stockley RA, Vogelmeier C, Anzueto A, Au DH, Barnes PJ, Burgel PR, Calverley PM, Casanova C, Clini EM, Cooper CB, Coxson HO, Dusser DJ, Fabbri LM, Fahy B, Ferguson GT, Fisher A, Fletcher MJ, Hayot M, Hurst JR, Jones PW, Mahler DA, Maltais F, Mannino DM, Martinez FJ, Miravitlles M, Meek PM, Papi A, Rabe KF, Roche N, Sciurba FC, Sethi S, Siafakas N, Sin DD, Soriano JB, Stoller JK, Tashkin DP, Troosters T, Verleden GM, Verschakelen J, Vestbo J, Walsh JW, Washko GR, Wise RA, Wouters EF, ZuWallack RL; ATS/ERS Task Force for COPD Research.

Eur Respir J. 2015 Apr;45(4):879-905. doi: 10.1183/09031936.00009015. Review.

23.

Reduced risk of nontuberculous mycobacteria in cystic fibrosis adults receiving long-term azithromycin.

Coolen N, Morand P, Martin C, Hubert D, Kanaan R, Chapron J, Honoré I, Dusser D, Audureau E, Veziris N, Burgel PR.

J Cyst Fibros. 2015 Sep;14(5):594-9. doi: 10.1016/j.jcf.2015.02.006. Epub 2015 Feb 28.

24.

Host-microbe interactions in distal airways: relevance to chronic airway diseases.

Martin C, Burgel PR, Lepage P, Andréjak C, de Blic J, Bourdin A, Brouard J, Chanez P, Dalphin JC, Deslée G, Deschildre A, Gosset P, Touqui L, Dusser D.

Eur Respir Rev. 2015 Mar;24(135):78-91. doi: 10.1183/09059180.00011614. Review.

25.

Complications of peripherally inserted central catheters in adults with cystic fibrosis or bronchiectasis.

Dupont C, Gouya H, Panzo R, Hubert D, Correas JM, Agrario L, Chapron J, Honoré I, Kanaan R, Legmann P, Dusser D, Vignaux O, Burgel PR.

J Vasc Access. 2015 May-Jun;16(3):245-9. doi: 10.5301/jva.5000347. Epub 2015 Feb 4.

PMID:
25656251
26.

Incidence of organizing pneumonia induced by oxaliplatin chemotherapy for digestive cancer.

Bellanger C, Dhooge M, Tabouret T, Chapron J, Dreanic J, Brezault C, Goldwasser F, Dusser D, Chaussade S, Coriat R.

Ann Pharmacother. 2015 Apr;49(4):494-5. doi: 10.1177/1060028015569595. Epub 2015 Jan 28. No abstract available.

PMID:
25632062
27.

Poor survival in rheumatoid arthritis associated with bronchiectasis: a family-based cohort study.

Puéchal X, Génin E, Bienvenu T, Le Jeunne C, Dusser DJ.

PLoS One. 2014 Oct 13;9(10):e110066. doi: 10.1371/journal.pone.0110066. eCollection 2014.

28.

Tiotropium might improve survival in subjects with COPD at high risk of mortality.

Burgel PR, Paillasseur JL, Dusser D, Roche N, Liu D, Liu Y, Furtwaengler A, Metzdorf N, Decramer M; UPLIFT® Study Investigators.

Respir Res. 2014 Jun 10;15:64. doi: 10.1186/1465-9921-15-64.

29.

Prognostic value of six minute walk test in cystic fibrosis adults.

Martin C, Chapron J, Hubert D, Kanaan R, Honoré I, Paillasseur JL, Aubourg F, Dinh-Xuan AT, Dusser D, Fajac I, Burgel PR.

Respir Med. 2013 Dec;107(12):1881-7. doi: 10.1016/j.rmed.2013.10.001. Epub 2013 Oct 11.

30.

Small airway impairment in moderate to severe asthmatics without significant proximal airway obstruction.

Perez T, Chanez P, Dusser D, Devillier P.

Respir Med. 2013 Nov;107(11):1667-74. doi: 10.1016/j.rmed.2013.08.009. Epub 2013 Aug 27.

31.

Tiotropium Respimat inhaler and the risk of death in COPD.

Wise RA, Anzueto A, Cotton D, Dahl R, Devins T, Disse B, Dusser D, Joseph E, Kattenbeck S, Koenen-Bergmann M, Pledger G, Calverley P; TIOSPIR Investigators.

N Engl J Med. 2013 Oct 17;369(16):1491-501. doi: 10.1056/NEJMoa1303342. Epub 2013 Aug 30.

32.

Rapid emergence of resistance to linezolid and mutator phenotypes in Staphylococcus aureus isolates from an adult cystic fibrosis patient.

Tazi A, Chapron J, Touak G, Longo M, Hubert D, Collobert G, Dusser D, Poyart C, Morand PC.

Antimicrob Agents Chemother. 2013 Oct;57(10):5186-8. doi: 10.1128/AAC.01392-13. Epub 2013 Aug 5.

33.

Small airways diseases, excluding asthma and COPD: an overview.

Burgel PR, Bergeron A, de Blic J, Bonniaud P, Bourdin A, Chanez P, Chinet T, Dalphin JC, Devillier P, Deschildre A, Didier A, Kambouchner M, Knoop C, Laurent F, Nunes H, Perez T, Roche N, Tillie-Leblond I, Dusser D.

Eur Respir Rev. 2013 Jun 1;22(128):131-47. doi: 10.1183/09059180.00001313.

34.

The Tiotropium Safety and Performance in Respimat Trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design and rationale.

Wise RA, Anzueto A, Calverley P, Dahl R, Dusser D, Pledger G, Koenen-Bergmann M, Joseph E, Cotton D, Disse B.

Respir Res. 2013 Apr 2;14:40. doi: 10.1186/1465-9921-14-40.

35.

CFTR dysfunction induces vascular endothelial growth factor synthesis in airway epithelium.

Martin C, Coolen N, Wu Y, Thévenot G, Touqui L, Prulière-Escabasse V, Papon JF, Coste A, Escudier E, Dusser DJ, Fajac I, Burgel PR.

Eur Respir J. 2013 Dec;42(6):1553-62. doi: 10.1183/09031936.00164212. Epub 2013 Mar 21.

36.

Association between Staphylococcus aureus alone or combined with Pseudomonas aeruginosa and the clinical condition of patients with cystic fibrosis.

Hubert D, Réglier-Poupet H, Sermet-Gaudelus I, Ferroni A, Le Bourgeois M, Burgel PR, Serreau R, Dusser D, Poyart C, Coste J.

J Cyst Fibros. 2013 Sep;12(5):497-503. doi: 10.1016/j.jcf.2012.12.003. Epub 2013 Jan 3.

37.

Two distinct chronic obstructive pulmonary disease (COPD) phenotypes are associated with high risk of mortality.

Burgel PR, Paillasseur JL, Peene B, Dusser D, Roche N, Coolen J, Troosters T, Decramer M, Janssens W.

PLoS One. 2012;7(12):e51048. doi: 10.1371/journal.pone.0051048. Epub 2012 Dec 7.

38.

[A new series on diseases affecting the distal airways].

Dusser D.

Rev Mal Respir. 2012 Dec;29(10):1185. doi: 10.1016/j.rmr.2012.11.004. French. No abstract available.

PMID:
23228676
39.

Bronchial rupture related to endobronchial stenting in relapsing polychondritis.

Chapron J, Wermert D, Le Pimpec-Barthes F, Cazes A, Pommier R, Hernigou A, Lacronique J, Dusser D, Burgel PR.

Eur Respir Rev. 2012 Dec 1;21(126):367-9. doi: 10.1183/09059180.00000612. No abstract available.

40.

[Prevention of COPD exacerbation: a fundamental challenge].

Roche N, Aguilaniu B, Burgel PR, Durand-Zaleski I, Dusser D, Escamilla R, Perez T, Raherison C, Similowski T; groupe d’expert « Exacerbations de BPCO ».

Rev Mal Respir. 2012 Jun;29(6):756-74. doi: 10.1016/j.rmr.2012.04.006. Epub 2012 Jun 6. Review. French.

PMID:
22742463
41.

Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer.

Mir O, Boudou-Rouquette P, Giroux J, Chapron J, Alexandre J, Gibault L, Ropert S, Coriat R, Durand JP, Burgel PR, Dusser D, Goldwasser F.

Lung Cancer. 2012 Jul;77(1):104-9. doi: 10.1016/j.lungcan.2012.01.014. Epub 2012 Feb 24.

PMID:
22364783
42.

[Lung volume reduction surgery for emphysema and bullous pulmonary emphysema].

Le Pimpec-Barthes F, Das Neves-Pereira JC, Cazes A, Arame A, Grima R, Hubsch JP, Zukerman C, Hernigou A, Badia A, Bagan P, Delclaux C, Dusser D, Riquet M.

Rev Pneumol Clin. 2012 Apr;68(2):131-45. doi: 10.1016/j.pneumo.2012.01.010. Epub 2012 Feb 22. Review. French.

PMID:
22361067
43.

[Eosinophilic pleural effusion related to taking valproic acid].

Bally C, Martin C, Kraoua S, Kanaan R, Lacronique J, Dusser D, Burgel PR.

Rev Pneumol Clin. 2011 Dec;67(6):363-6. doi: 10.1016/j.pneumo.2010.11.008. Epub 2011 Apr 29. French.

PMID:
22137281
44.

High prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole.

Burgel PR, Baixench MT, Amsellem M, Audureau E, Chapron J, Kanaan R, Honoré I, Dupouy-Camet J, Dusser D, Klaassen CH, Meis JF, Hubert D, Paugam A.

Antimicrob Agents Chemother. 2012 Feb;56(2):869-74. doi: 10.1128/AAC.05077-11. Epub 2011 Nov 28.

45.

Employment and work disability in adults with cystic fibrosis.

Laborde-Castérot H, Donnay C, Chapron J, Burgel PR, Kanaan R, Honoré I, Dusser D, Choudat D, Hubert D.

J Cyst Fibros. 2012 Mar;11(2):137-43. doi: 10.1016/j.jcf.2011.10.008. Epub 2011 Nov 21.

46.

[Symptoms and natural history of COPD: role of the distal airways].

Chaouat A, Chabot F, Dusser D.

Rev Mal Respir. 2011 Oct;28(8):1071-8. doi: 10.1016/j.rmr.2011.08.004. Epub 2011 Oct 28. Review. French.

PMID:
22099412
47.

Should bronchoscopy be advocated to study airway remodelling and inflammation in adults with cystic fibrosis?

Burgel PR, Martin C, Fajac I, Dusser DJ.

Thorax. 2012 Feb;67(2):177; author reply 177. doi: 10.1136/thoraxjnl-2011-200824. Epub 2011 Oct 11. No abstract available.

PMID:
21989735
48.

A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma.

Faivre L, Gomo C, Mir O, Taieb F, Schoemann-Thomas A, Ropert S, Vidal M, Dusser D, Dauphin A, Goldwasser F, Blanchet B.

J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Aug 1;879(23):2345-50. doi: 10.1016/j.jchromb.2011.06.026. Epub 2011 Jun 22.

PMID:
21737360
49.

Liver disease in adult patients with cystic fibrosis: a frequent and independent prognostic factor associated with death or lung transplantation.

Chryssostalis A, Hubert D, Coste J, Kanaan R, Burgel PR, Desmazes-Dufeu N, Soubrane O, Dusser D, Sogni P.

J Hepatol. 2011 Dec;55(6):1377-82. doi: 10.1016/j.jhep.2011.03.028. Epub 2011 May 19.

PMID:
21703187
50.

Safety of bevacizumab 7.5 mg/kg infusion over 10 minutes in NSCLC patients.

Mir O, Alexandre J, Coriat R, Ropert S, Boudou-Rouquette P, Bui T, Chapron J, Durand JP, Dusser D, Goldwasser F.

Invest New Drugs. 2012 Aug;30(4):1756-60. doi: 10.1007/s10637-011-9690-9. Epub 2011 May 26.

PMID:
21614447

Supplemental Content

Loading ...
Support Center